Northland Capmk Forecasts Stronger Earnings for Indivior

Indivior PLC (NASDAQ:INDV - Free Report) - Equities researchers at Northland Capmk upped their FY2025 earnings per share estimates for shares of Indivior in a research note issued on Thursday, April 24th. Northland Capmk analyst C. Byrnes now expects that the company will earn $1.15 per share for the year, up from their prior forecast of $0.90. The consensus estimate for Indivior's current full-year earnings is $1.22 per share.

Other research analysts have also recently issued research reports about the company. Rodman & Renshaw started coverage on Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock. Piper Sandler decreased their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th.

Indivior Price Performance

Indivior stock traded up $0.37 during mid-day trading on Monday, reaching $11.92. 119,095 shares of the company were exchanged, compared to its average volume of 975,741. The firm has a market cap of $1.64 billion, a PE ratio of -33.95 and a beta of 0.93. The company has a fifty day simple moving average of $9.68 and a 200-day simple moving average of $10.41. Indivior has a 12 month low of $7.33 and a 12 month high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund acquired a new stake in shares of Indivior in the 1st quarter valued at approximately $295,000. Cannon Global Investment Management LLC acquired a new position in shares of Indivior during the first quarter worth $95,000. Schaper Benz & Wise Investment Counsel Inc. WI acquired a new position in shares of Indivior during the first quarter worth $95,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Indivior by 48.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 142,444 shares of the company's stock valued at $1,357,000 after acquiring an additional 46,509 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Indivior during the 4th quarter valued at $36,000. Institutional investors and hedge funds own 60.33% of the company's stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.